FDA 'Concerned' after Germany Reports More Heparin-Related Illnesses - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA 'Concerned' after Germany Reports More Heparin-Related Illnesses


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Rockville, MD (Mar. 6)—Concerns over contaminated heparin product worsened as US officials announced dialysis patients in Germany have fallen ill after using a different brand of the blood thinner than was already being recalled.

Just one week after Baxter International announced it would voluntary recall all of its remaining lots and doses of heparin sodium injection multidose, single-dose vials, and HEP-LOK heparin flush products, which were linked to 19 deaths in the United States, FDA confirmed that Germany is recalling heparin made by RotexMedica GmbH, a German company that uses a different supplier of raw heparin ingredients than Baxter does. Baxter receives its heparin material from China, the world’s largest heparin supplier. It is unknown whether RotexMedica also received its supply from China.

The incidents appear to be caused by a contaminant that mimics heparin so well that it is not detected by standard drug-quality tests. In response, FDA is urgently pushing for companies to start using advanced analytical techniques to ensure drug products are free of this contaminant and has posted instructions on its website on how manufacturers can do these additional tests to identify the fake ingredient.

“We’re concerned about, worldwide, this contaminant in heparin and making sure it stays out of the heparin supply,” said Janet Woodcock, FDA chief medical officer, to the Associated Press.

Reports have stated that German officials have not confirmed that the heparin product by RotexMedica has been recalled. Meanwhile, as reported in the February 28 edition of ePT, APP Pharmaceuticals has boosted its manufacture in efforts to keep up with market demand.

For more on this topic, see:

Active Ingredient in Baxter's Recalled Heparin Made in China, Feb. 21 edition of ePT

Baxter Voluntarily Recalls Heparin Lots, Feb. 14 edition of ePT

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here